logo.png
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
September 26, 2019 16:19 ET | Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
logo.png
Adhera Therapeutics Announces Termination of Tender Offer for Warrants
July 02, 2019 16:15 ET | Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
October 09, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
logo.png
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
October 19, 2017 08:30 ET | Marina Biotech, Inc.
City of Industry, CA, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...